Biodegradable Dendritic Polyglycerol Sulfate for the Delivery and Tumor Accumulation of Cytostatic Anticancer Drugs
- 1 June 2021
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 7 (6) , 2569-2579
Abstract
Targeted delivery and extended blood circulation of anticancer drugs have been the challenges for decreasing the adverse side effects and improving the therapeutic efficiency in cancer chemotherapy. Herein, we present a drug delivery system (DDS) based on biodegradable dendritic polyglycerol sulfate-bearing poly(caprolactone) (dPGS-PCL) chains, which has been synthesized on 20 g scale using a straightforward two-step protocol. In vivo fluorescence imaging demonstrated a significant accumulation of the DDS in the tumor environment. Sunitinib, an anticancer drug, was loaded into the DDS and the drug-induced toxicity was investigated in vitro and in vivo. The drug encapsulated in dPGS-PCL and the free drug showed similar toxicities in A431 and HT-29 cells, and the cellular uptake was comparable. The straightforward and large-scale synthesis, the organic solvent-free drug-loading approach, together with the tumor targetability of the biodegradable dendritic polyglycerols, render this copolymer a promising candidate for targeted cancer nanomedicine drug delivery systems.Keywords
Funding Information
- Helmholtz-Gemeinschaft (Helmholtz Graduate School for Macromolecular Biosc)
- Deutsche Forschungsgemeinschaft (BioSupraMol)
This publication has 48 references indexed in Scilit:
- Dendritic polyglycerol sulfates as multivalent inhibitors of inflammationProceedings of the National Academy of Sciences, 2010
- Immunity, Inflammation, and CancerCell, 2010
- Cancer-related inflammationNature, 2008
- Cardiotoxicity associated with the cancer therapeutic agent sunitinib malateAnnals of Oncology, 2008
- Nanocarriers as an emerging platform for cancer therapyNature Nanotechnology, 2007
- Photochemical and Chemical Two‐Channel Control of Functional Nanogated Hybrid ArchitecturesAdvanced Materials, 2007
- Clinical translation of angiogenesis inhibitorsNature Reviews Cancer, 2002
- Developing aptamers into therapeuticsJournal of Clinical Investigation, 2000
- The Hallmarks of CancerCell, 2000
- Distribution of the transferrin receptor in normal human fibroblasts and fibrosarcoma cellsInternational Journal of Cancer, 1983